SG Americas Securities
ALXN

SG Americas Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

SG Americas Securities’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,400
Closed -$10K – 3409
2021
Q1 		$10K Sell
15,400
-184,000
-92% -$28.5M ﹤0.01% 3216
2020
Q4 		$32K Buy
199,400
+15,400
+8% +$1.98M ﹤0.01% 3179
2020
Q3 		$1.06M Sell
184,000
-78,100
-30% -$8.43M 0.01% 1139
2020
Q2 		$1.36M Buy
262,100
+112,600
+75% +$12M 0.01% 1122
2020
Q1 		$608K Buy
149,500
+134,500
+897% +$13.2M 0.01% 1682
2019
Q4 		$69K Buy
+15,000
New +$1.6M ﹤0.01% 3021
2018
Q1 		– Sell
-49,500
Closed -$554K – 3659
2017
Q4 		$554K Hold
49,500
– – 0.01% 1783
2017
Q3 		$242K Hold
49,500
– – ﹤0.01% 2432
2017
Q2 		$902K Hold
49,500
– – 0.01% 1482
2017
Q1 		$1.02M Hold
49,500
– – 0.01% 1351
2016
Q4 		$1.24M Hold
49,500
– – 0.01% 1175
2016
Q3 		$1.15M Hold
49,500
– – 0.01% 1067
2016
Q2 		$1.5M Buy
+49,500
New +$7.02M 0.01% 1028

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

SG Americas Securities's ALXN Position: Q3 2021 in Review

SG Americas Securities sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 17,511 shares — an estimated $3.22M sold.

SG Americas Securities first reported a position in ALXN in Q2 2013 and held it in 32 quarters. The position peaked at $38.4M in Q1 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • SG Americas Securities reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • SG Americas Securities sold 17,511 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.22M.
  • SG Americas Securities first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 32 quarters.
  • SG Americas Securities's Alexion Pharmaceuticals position peaked at $38.4M in Q1 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on SG Americas Securities's 13F filing for Q3 2021, filed 1 Nov 2021.